ANTIBODY-DRUG CONJUGATES (ADCS) :
TRANSFORMING TARGETED CANCER THERAPIES
Author: Marie Tautou, Director of Scientific studies
Antibody-drug conjugates (ADCs) represent a major advance in the fight against cancer. These innovative therapies act as veritable “homing missiles”, directly targeting cancer cells while sparing healthy tissue. By combining the specificity of monoclonal antibodies with the potency of cytotoxic agents, ADCs are emerging as one of the most promising forms of targeted therapy, offering patients more effective and less toxic treatment options.At Antineo, we are committed to supporting our customers in demonstrating the efficacy and safety of their ADCs, in order to make cancer treatments more precise and patient-friendly.